Actively Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Led by NHS Greater Glasgow and Clyde · Updated on 2025-06-19
50
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
Sponsors
N
NHS Greater Glasgow and Clyde
Lead Sponsor
U
University of Glasgow
Collaborating Sponsor
AI-Summary
What this Trial Is About
The investigators seek clinically actionable understanding of the mechanisms that underlie depression in the context of immune mediated inflammatory diseases (IMIDs), delivered by a focused immune intervention study examining brain circuitry using state of the art imaging in the context of exquisitely specific therapeutic immune interception in human immune disease. Glutamate concentration in the NAcc will be positively correlated with the magnitude of the inflammatory response and will be attenuated by IL-17A inhibition. Ultimately, this will be associated with an improvement in depressive symptoms. The strength of coupling between early and late systems will be attenuated in the context of IL-17A-driven inflammation and will be correlated with less frequent switching behaviour following negative outcomes and ultimately depressive symptoms. This coupling will be re-established following IL-17 antagonism. Patients whose depressive symptoms benefit most from IL-17A antagonism will exhibit greatest resting-state and task-specific functional connectivity between Th-NAcc.
CONDITIONS
Official Title
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to less than 75 years
- Diagnosis of psoriasis or psoriatic arthritis by a dermatologist or rheumatologist
- Selected to start secukinumab, bimekizumab, or ixekizumab as part of standard clinical care
- No contraindications to MRI (including metal fragments or incompatible implantable devices)
- Completion of standard pre-biologic safety screening including exclusion of latent TB, chest X-ray, negative HIV and hepatitis tests
- No intra-muscular or intra-articular steroid injections within 4 weeks prior to baseline
- Women of child-bearing potential willing to use effective contraception during the study
- Willing to participate and provide informed consent
You will not qualify if you...
- Unable to provide written informed consent
- Severe physical impairments such as blindness, deafness, or paraplegia
- Active serious infections like active tuberculosis
- History of inflammatory bowel disease
- Pregnant or breastfeeding
- Severe claustrophobia preventing MRI
- Contraindications to 7T MRI such as metal implants in ears, head, or neck, microbladed or tattooed eyebrows, or metal fragments in eyes
- Confounding neurological diseases including multiple sclerosis, stroke, or traumatic brain injury
- Prior exposure to IL-17A, IL-17A/F, IL-17R, or IL-23 inhibitors within the last 6 months
- Allergic reaction to any ingredients in secukinumab, bimekizumab, or ixekizumab
- Any condition making participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Queen Elizabeth University Hospital
Glasgow, Scotland, United Kingdom, G51 4TF
Actively Recruiting
Research Team
M
Maxine Arnott, BSc
CONTACT
N
Neil Basu, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here